AstraZeneca Seals China Obesity Drug Deal For Up To $18.5B
Biotechnology giant AstraZeneca has struck a licensing deal worth up to $18.5 billion with CSPC Pharmaceutical of China to develop weight-loss drugs, the companies said Friday, as Western investment in China...To view the full article, register now.
Already a subscriber? Click here to view full article